Researchers from Boehringer Ingelheim Pharma GmbH & Co KG presented the discovery and preclinical characterization of new spleen tyrosine kinase (SYK) inhibitors, BI-894416 and BI-1342561, being ...
Hutchmed is gearing up to submit sovleplenib for approval in the company’s native China after the Syk inhibitor scored a phase 3 win. The placebo-controlled trial enrolled 188 adults in China with ...
Cevidoplenib is an investigational SYK inhibitor designed to inhibit the downstream signaling of B-cell and Fc receptors resulting in increased platelet counts. The Food and Drug Administration (FDA) ...
The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results